tradingkey.logo

Maravai LifeSciences Holdings Inc

MRVI
查看詳細走勢圖
3.140USD
+0.050+1.62%
收盤 02/06, 16:00美東報價延遲15分鐘
454.41M總市值
虧損本益比TTM

Maravai LifeSciences Holdings Inc

3.140
+0.050+1.62%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.62%

5天

-6.55%

1月

-18.65%

6月

+55.06%

今年開始到現在

-3.38%

1年

-31.44%

查看詳細走勢圖

操作建議

Maravai LifeSciences Holdings Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名96/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為3.93。中期看,股價處於平穩狀態。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Maravai LifeSciences Holdings Inc評分

相關信息

行業排名
96 / 392
全市場排名
224 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Maravai LifeSciences Holdings Inc亮點

亮點風險
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
估值合理
公司最新PE估值-3.74,處於3年歷史合理位
機構減倉
最新機構持股130.36M股,環比減少22.89%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉14.30K股

分析師目標

基於 11 分析師
買入
評級
3.929
目標均價
+20.14%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Maravai LifeSciences Holdings Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Maravai LifeSciences Holdings Inc簡介

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
公司代碼MRVI
公司Maravai LifeSciences Holdings Inc
CEOBrust (Bernd)
網址https://www.maravai.com/
KeyAI